Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study - Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michaël Duruisseaux, Lucie Ulmer, Pascal Wang, Etienne ...
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial | Journal of Clinical Oncology
News Articles | ESMO
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
Figure 2 from Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. | Semantic Scholar
When more is better: bevacizumab treatment for patients with ovarian cancer | Fred Hutchinson Cancer Center
JAMA on X: "Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial | International
Adding Olaparib to Bevacizumab Maintenance Improves Progression
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study - ScienceDirect
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Oncology
![PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1f2882819a61e3853acfa2fdb64e9ae4bb6b3252/5-Figure2-1.png "PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar")
PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Overall survival and progression-free survival by hyper | Open-i
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma | Journal of Neuro-Oncology
IMbrave 151 missed primary endpoint in advanced BTC - Medical Conferences
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma | American Journal of Neuroradiology
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC - Medical Conferences
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
Cancers | Free Full-Text | Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial - ScienceDirect
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
